Skip to main content
. Author manuscript; available in PMC: 2019 Jun 26.
Published in final edited form as: Exp Mol Pathol. 2015 Sep 25;99(3):498–505. doi: 10.1016/j.yexmp.2015.09.007

Figure 1. Expression of RGC-32, FasL, CDC2, AKT, and IL-21 mRNA in stable MS patients and patients with acute relapses.

Figure 1.

Target gene mRNA expression was measured in patients’ PBMCs using real-time qRT-PCR and expressed as a ratio to L13. A. Significantly lower levels of RGC-32 mRNA were found in patients with relapses compared to clinically stable patients (p<0.0001). B. Significantly lower levels of FasL mRNA were found in patients with relapses compared to clinically stable patients (p<0.0001). C and D. No statistically significant changes were observed in CDC2 or AKT mRNA. E. Significantly higher levels of IL-21 mRNA were found in patients with relapses compared to clinically stable patients (p=0.04). F. RGC-32 mRNA expression levels were correlated with those of FasL in patients during relapses (r=0.90, p<0.0001).